France Dengue Diagnostics Market Size, Share, and COVID-19 Impact Analysis, By Product (ELISA-based Tests, Dengue IgG/IgM Detection Kits, RT-PCR Tests, Rapid Diagnostic Tests (RDTs), NS1 Antigen Detection Kits, and Lateral Flow Immunoassay), By Service Type (Centralized Service and POC Service), and France Dengue Diagnostics Market Insights, Industry Trend, Forecasts to 2035

France Dengue Diagnostics Market Insights Forecasts to 2035

• The France Dengue Diagnostics Market Size was Estimated at USD 8.72 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 0.97% from 2025 to 2035
• The France Dengue Diagnostics Market Size is Expected to Reach USD 9.70 Million by 2035

The France Dengue Diagnostics Market Size is anticipated to reach USD 9.70 Million by 2035, Growing at a CAGR of 0.97% from 2025 to 2035. The France dengue diagnostics market is driven by rising travel-related cases, increased awareness, and advancements in rapid diagnostic technologies.

Market Overview

The France dengue diagnostics market focuses on the detection and identification of dengue fever, a mosquito-borne viral illness caused by the dengue virus. Though not endemic to France, cases often arise due to travel from tropical and subtropical regions, making diagnostics an essential part of healthcare preparedness. The market includes various diagnostic approaches such as molecular tests like polymerase chain reaction (PCR), serological tests like enzyme-linked immunosorbent assay (ELISA), and rapid diagnostic tests (RDTs). These methods are used in hospitals, diagnostic laboratories, and research institutions across the country. The diagnostics industry in France is supported by a well-developed healthcare infrastructure and regulatory framework, ensuring the availability of accurate and timely testing services. The market serves both clinical and public health needs, aiding in patient care and outbreak monitoring. With a focus on early and precise detection, the dengue diagnostics market plays a crucial role in managing and mitigating potential dengue-related health issues.

Report Coverage

This research report categorizes the market for the France dengue diagnostics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France dengue diagnostics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France dengue diagnostics market.

Driving Factors

Increasing international travel has led to a rise in imported dengue cases, prompting the need for efficient diagnostic solutions. Climate change and warmer temperatures have also contributed to the spread of dengue-carrying mosquitoes in parts of Europe, including southern France. Additionally, advancements in diagnostic technologies, such as rapid tests and molecular assays, have improved detection accuracy and speed. Public health initiatives and government support for infectious disease surveillance further boost market growth. Heightened awareness among healthcare professionals and the general population also supports the increasing demand for early dengue diagnosis.

Restraining Factors

The lack of widespread endemic dengue transmission in France reduces the frequency of testing, affecting market demand. Additionally, regulatory hurdles and the need for specialized training in diagnostic techniques can slow adoption.

Market Segmentation

The France dengue diagnostics market share is classified into product and service type.

• The RT-PCR tests segment held the largest market share in 2024 and is expected to grow at a substantial CAGR during the forecast period.

The France dengue diagnostics market is segmented by product into ELISA-based tests, dengue IgG/IgM detection kits, RT-PCR tests, rapid diagnostic tests (RDTs), NS1 antigen detection kits, and lateral flow immunoassay. Among these, the RT-PCR tests segment held the largest market share in 2024 and is expected to grow at a substantial CAGR during the forecast period. RT-PCR tests are favored for their high accuracy in detecting the dengue virus at an early stage by identifying the virus's genetic material. The increasing preference for molecular diagnostics due to their sensitivity and reliability is driving this growth.

• The POC service segment held the highest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The France dengue diagnostics market is segmented by service type into centralized service and POC service. Among these, the POC service segment held the highest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. POC services are increasingly preferred due to their ability to provide rapid and convenient results at or near the site of patient care, minimizing wait times and enabling quicker clinical decision-making. The growing demand for faster, on-the-spot diagnosis, especially in remote areas or busy clinics, is driving the adoption of POC services.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France dengue diagnostics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• BioMérieux
• Quidel Corporation
• BD (Becton, Dickinson and Company)
• Wondfo Biotech
• Creative Diagnostics
• MedSource Laboratories
• Others

Recent Developments:

• In April 2021, Wondfo launched a rapid NS1 antigen detection kit, providing a reliable tool for diagnosing acute dengue infection, enabling faster treatment and containment.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at France, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the France dengue diagnostics market based on the below-mentioned segments:

France Dengue Diagnostics Market, By Product

• ELISA-based Tests
• Dengue IgG/IgM Detection Kits
• RT-PCR Tests
• Rapid Diagnostic Tests (RDTs)
• NS1 Antigen Detection Kits
• Lateral Flow Immunoassay

France Dengue Diagnostics Market, By Service Type

• Centralized Service
• POC Service